C-PATROL - a Single Arm, Prospective Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population

简要总结

主要结局

次要结局

• Progression-free survival 2 (PFS2)(Date of first administration of first subsequent therapy to date of progression as assessed by the investigator or death, assessed approximately up to 84 months)
• Time to discontinuation of olaparib monotherapy (TDO)(Date of first documented dose of olaparib montherapy to date of last documented dose of olaparib monotherapy or death whichever occurred before, assessed approximately up to 84 months)
• Safety of Olaparib: collection of Adverse Events (AE)(Date of first documented dose of Olaparib to last visit, assessed approximately up to 84 months)
• To collect and explore real-life data on patient outcomes in terms of Overall Survival (OS)(Date of first documented dose of olaparib to death of any cause, assessed approximately up to 84 months)
• Time to second subsequent therapy (TSST)(Date of first documented dose of olaparib to date of first administration of second subsequent therapy or death if this occurs before commencement of second subsequent treatment, assessed approximately up to 84 months)
• Time to first subsequent therapy (TFST)(Date of first documented dose of olaparib to date of first administration of first subsequent therapy or death if this occurs before commencement of first subsequent treatment, assessed approximately up to 84 months)
• Assessment of health-related quality of life (HRQoL) in patients participating in the study.(Date of first visit to last visit. HRQoL are collected every 3 months up to 84 months)